Lenacapravir treats and prevents HIV, it does not cure infection | Fact check
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
Politifact7h
This drug helps manage infections and prevent AIDS, but claims it’s a ‘cure’ are not supported
"Currently, there is no therapeutic cure for HIV," Sheryl Zwerski, who holds a Doctor of Nursing Practice and directs the Prevention Sciences Program at the National Institute of Allergy and ...
Gilead Sciences’ Strategic Focus on Lenacapavir and Lifecycle Management Drives Buy Rating
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...
Neurology Advisor1d
Incidence of HIV Lower With Twice-Yearly Subcutaneous Lenacapavir
The incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir compared with daily oral emtricitabine-tenofovir disoproxil fumarate.
Fact Check: HIV drug prevents infections, but not a new 'cure' for AIDS
A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...
Medical News Today8d
Lenacapavir injection lowers HIV risk by 96%
Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
Gilead Sciences: Long-Term Growth Prospects in HIV Treatment Drive Buy Rating
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...
FOX 5 Atlanta on MSN4d
HIV gamechanger: Lenacapavir study participant explains
FOX 5 spoke exclusively with a participant in a study for a new injectable drug to prevent HIV. Emory University medical ...
Interesting Engineering on MSN9d
From chronic to curable: Twice-yearly shot shows near-total HIV eradication
Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
GlobalData on MSN13d
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
Gilead Sciences has announced the outcomes from the randomised Phase III PURPOSE 2 trial evaluating lenacapavir for human ...
AOL8d
Lenacapavir injection lowers HIV risk by 96%
The lenacapavir group also received 2 initial ... highlighted the following components of the study’s findings to Medical News Today: “There were only two incident cases of HIV infection ...